AI assistant
Sending…
UroGen Pharma Ltd. — Director's Dealing 2023
Jul 28, 2023
32312_dirs_2023-07-28_12b28c38-3358-4455-bef6-d99651b8d529.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2023-07-26
Reporting Person: Cohen Fred E (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-07-26 | Ordinary Shares | A | 69339 | $9.54 | Acquired | 69339 | Indirect |
Footnotes
F1: Represents the reporting person's proportionate interest in shares acquired by entities affiliated with Monograph Capital Partners, for which the reporting person is Chair and Chief Investment Officer
More from UroGen Pharma Ltd.
Annual Report
2026
May 27
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Proxy Solicitation & Information Statement
2026
Apr 30
Annual Report
2026
Mar 2
Regulatory Filings
2026
Mar 2
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 27
Director's Dealing
2026
Feb 19
Director's Dealing
2026
Feb 11